Methods of increasing delivery of active agents to brain...

Details Methods of increasing delivery of active agents to brain... Methods of increasing delivery of active agents to brain...

2004-03-30

2009-08-04

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07569544

ABSTRACT:
The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.

REFERENCES:
patent: 4018884 (1977-04-01), Cleeland, Jr. et al.
patent: 4391904 (1983-07-01), Litman et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4744981 (1988-05-01), Pavanasasivam
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5106951 (1992-04-01), Morgan, Jr. et al.
patent: 5186941 (1993-02-01), Callahan et al.
patent: 5474766 (1995-12-01), Schwartz et al.
patent: 5962012 (1999-10-01), Lin et al.
patent: 5981194 (1999-11-01), Jefferies et al.
patent: 6261595 (2001-07-01), Stanley et al.
patent: 6447775 (2002-09-01), Strickland et al.
patent: 6743427 (2004-06-01), Schenk
patent: 6919311 (2005-07-01), Lenting et al.
patent: 2003/0129186 (2003-07-01), Beliveau
patent: 2007/0083334 (2007-04-01), Mintz et al.
patent: WO 00/28021 (2000-05-01), None
patent: WO 00/71714 (2000-11-01), None
patent: WO 01/59459 (2001-08-01), None
patent: WO 02/13843 (2002-02-01), None
patent: WO03/009815 (2003-02-01), None
Perez-Navarro 2000. Journal of Neurochemistry 75:2190-2199.
Zlokovic 1996. Proc Natal Acad Sci USA 93:4229-4234.
Pardridge 2002. Nature Reviews Drug Discovery 1:131-139.
Altschul et al.,J. Mol. Biol.,215(3):403-410 (1990).
Ashcom et al.,J. Cell. Biol.,110(4):1041-1048 (1990).
Bickel et al.,Adv. Drug Deliv. Rev.,46(1-3):247-279 (2001).
Blair et al.,J. Immunol. Methods,59(2):129-143 (1983).
Blättler et al.,Biochem.,24:1517-1524 (1985).
Bu et al.,J. Biol. Chem.,271(36):22218-2224 (1996).
Bu et al.,Trends Cell. Biol.,8(7):272-276 (1998).
Czekay et al.,Mol. Biol. Cell.,8(3):517-532 (1997).
Dehouck et al.,J. Cell. Biol.,138(4):877-889 (1997).
Fahrlander et al.,Bio/Technology,6:1165-1168 (1988).
Feng et al.,J. Mol. Evol.,25:351-360 (1987).
Fillebeen et al.,J. Biol. Chem.,274(11):7011-7017 (1999).
FitzGerald et al.,J. Cell Biol.,129(6):1533-1541 (1995).
Genbank Accession No. AAH49517.
Genbank Accession No. AAM90301.
Genbank Accession No. CAA05085.
Genbank Accession No. NP—506187.
Genbank Accession No. NP—649950.
Genbank Accession No. P30533.
Genbank Accession No. Q99068.
Genbank Accession No. X13916.
Genbank Accession No. XP—132029.
Genbank Accession No. XP—313261.
Gutierrez et al.,J. Neuroimmunology,47(2):169-176 (1993).
Henikoff et al.,Proc. Natl. Acad. Sci. USA,89:10915 (1989).
Herz et al.,Atherosclerosis,118 Suppl:S37-S41 (1995).
Herz et al.,J. Biol. Chem.,266(32):21232-21238 (1991).
Herz et al.,J. Clin. Invest.,108(6):779-784 (2001).
Higgins et al.,Comput. Appl. Biosci.,5(2):151-153 (1989).
Hoogerbrugge et al.,Lancet,345(8962):1398-1402 (1995).
Jensen et al.,FEBS Lett.,225(2):275-280 (1989).
Karlin et al.,Proc. Natl. Acad. Sci. USA,90(12):5873-5877 (1993).
Kilic et al.,Stroke,34(5):1304-1310 (2003).
King et al.,Biochem.,25(19):5774-5779 (1986).
Kushuhara et al.,Drug Discov. Today,6(3):150-156 (2001).
Lin et al.,Science,260(5111):1130-1132 (1993).
Medved et al.,J. Biol. Chem.,274(2):717-727 (1999).
Meilinger et al.,FEBS Lett.,360(1):70-74 (1995).
Melman et al.,J. Biol. Chem.,276(31):29338-29346 (2001).
Needleman et al.,J. Mol. Biol.,48(3)443-453 (1970).
Nielsen et al.,Proc. Natl. Acad. Sci. USA,94(14):7521-7525 (1997).
Orlando et al.,Proc. Natl. Acad. Sci. USA,91(8):3161-3165 (1994).
Pardridge,J. Neurovirol.,5(6):556-569 (1999).
Pearson et al.,Proc. Natl. Acad. Sci. USA,85(8):2444-2448 (1988).
Rall et al.,J. Biol. Chem.,273(37):24152-24157 (1998).
Savonen et al.,J. Biol. Chem.,274(36):25877-25882 (1999).
Smith et al.,Adv. Appl. Math.,2:482-489 (1981).
Srinivasachar et al.,Biochem.,28(6):2501-2509 (1989).
SwissProt Primary Accession No. Q07954.
Takahashi et al.,Proc. Natl. Acad. Sci. USA,89(19):9252-9256 (1992).
Thompson et al.,Nucleic Acids Res.,22(22):4673-4680 (1994).
Tsuji et al.,Adv. Drug Deliv. Rev.,36(2-3):277-290 (1999).
Warshawsky et al.,J. Biol. Chem.,269(5):3325-3330 (1994).
Wilchek et al.,Anal. Biochem.,171:1-32 (1988).
Williams et al.,J. Biol. Chem.,267(13):9035-9040 (1992).
Willnow et al.,J. Biol. Chem.,267(36):26172-26180 (1992).
Wisselaar et al.,J. Biol. Chem.,268(3):2223-2231 (1993).
Yenofsky et al.,Proc. Natl. Acad. Sci. USA,87(9):3435-3439 (1990).
Canals et al., J. Neuroscience, 24(35):7727-7739 (2004).
Ferrer et al., Brain Research, 866, 257-261 (2000).
Kells et al., Molecular Therapy, 9 (5) 682-688 (2004).
Spires, et al., J. Neuroscience, 24(9) 2270-2276 (2004).
Zuccato et al., Science, 293, 493-498 (2001).
Anderson et al., “Differential Binding of Ligands to the Apolipoprotein E Receptor 2,”Biochemistry,42:9355-9364 (2003).
Anderson et al., “Dominant Thermodynamic Role of the Third Independent Receptor Binding Site in the Receptor-Associated Protein RAP,”Biochemistry,40:15408-15417 (2001).
Anderson et al., “Identification of the Minimal Functional Unit in the Low Density Lipoprotein Receptor-related Protein for Binding the Receptor-associated Protein (RAP),”J. Biol. Chem.,275(28)21017-21024 (2000).
Bajari et al., “A Minimal Binding Domain of the Low Density Lipoprotein Receptor Family,”Biol. Chem.,379:1053-1062 (1998).
Bickel et al., “Pharmacologic Effects in Vivo in Brain by Vector-mediated Peptide Drug Delivery,”Proc. Natl. Acad. Sci. USA,90:2618-2622 (1993).
Bogan et al., “Anatomy of Hot Spots in Protein Interfaces,”J. Mol. Biol.,280:1-9 (1998).
Bu, “The Roles of Receptor-Associated Protein (RAP) as a Molecular Chaperone for Members of the LDL Receptor Family,”Int. Rev. Cytol.,209:79-116 (2001).
Clackson et al., “A Hot Spot of Binding Energy in a Hormone-receptor Interface,”Science,267:383-386 (1995).
DeLano, “Unraveling Hot Spots in Binding Interfaces: Progress and Challenges,”Curr. Opin. Struct. Biol.,12:14-20 (2002).
Dwyer et al., “High Affinity RNase S-Peptide Variants Obtained by Phage Display Have a Novel Hot-Spot of Binding Energy,”Biochemistry,40:13491-13500 (2001).
Fisher et al., “Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors,”Molecular Cell,22:277-283 (2006).
Gao et al., “Structure-based Method for Analyzing Protein-Protein Interfaces,”J. Mol. Model,10:4-54 (2004).
Halperin et al., “Protein-Protein Interactions: Coupling of Structurally Conserved Residues and of Hot Spot Across Interfaces. Implications for Docking,”Structure,12:1027-1038 (2004).
Horn et al., “Molecular Analysis of Ligand Binding to the Second Cluster of Complement-type Repeats of the Low Density Lipoprotein Receptor-related Protein,”J. Biol. Chem.,272(21):13608-13613 (1997).
Jensen et al., “Binding Site Structure of One LRP-RAP Complex: Implications for a Common Ligand-Receptor Binding Motif,”J. Mol. Biol.,362:700-716 (2006).
Kounnas et al., “The 39-kDa Receptor-Associated Protein Interacts with Two Members of the Low Density Lipoprotein Receptor Family, α2-Macroglobulin Receptor and Glycoprotein 330,”J. Biol. Chem.,267(29):21162-21166 (1992).
Lee et al., “RAP Uses a Histidine Switch to Regulate its Interaction with LRP in the ER and Golgi,”Mol. Cell,22:423-430 (2006).0.
Li et al., “Magnitude of the Hydrophobic Effect at Central Versus Peripheral Sites in Protein-Protein Interfaces,”Structure,13:297-307 (2005).
Lisi et al., “Preferential Megalin-mediated Transcytosis of Low-hormonogenic Thyroglobulin: a Control Mechanism for Thyroid Hormone Release,”Proc. Natl. Acad. Sci. USA,100(25):14858-14863 (2003).
McCormick et al., “Independent and Cooperative Roles of N-Glycans and Molecular Chaperones in the Folding and Disulfide Bond Formation of the Low-Density Lipoprotein (LDL) Receptor-Related Protein,”Biochemistry,44:5794-5803 (2005).
Migliorini et al., “Allosteric Modulation of Ligand Binding to Low Density Lipoprotein Receptor-related Protein by the Receptor-associated Protein Requires Critical L

Affiliated with

Also associated with

Rating

Methods of increasing delivery of active agents to brain... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of increasing delivery of active agents to brain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of increasing delivery of active agents to brain... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077639